Form 4 Filing for George Simeon

This SEC filing details transactions made by George Simeon, a director at CRISPR Therapeutics AG, on October 14, 2026. Simeon acquired 30,000 Common Shares under a Rule 10b5-1 trading plan, with the transaction code "M". This acquisition was linked to the exercise of a stock option for the same number of shares, priced at $14 per share. Subsequently, Simeon disposed of 14,514 Common Shares at a weighted average price of $49.633 per share, with sales ranging from $49.45 to $50.44. This disposal was also conducted under the Rule 10b5-1 trading plan. Following these transactions, Simeon